YSYoshihiko Segawa

Yoshihiko Segawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshihiko Segawa has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • H. Isobe

    Department of Respiratory Disease, National Hospital Organization Hokkaido Cancer Center, Hokkaido

    1 shared publication
  • Haruyuki Kawai

    Department of Medicine, Okayama Saiseikai General Hospital, Okayama, Japan

    1 shared publication
  • Hidetoshi Hayashi

    Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan

    1 shared publication
  • Hiroshi Ueoka

    Department of Respiratory Medicine, National Hospital Organization Yamaguchi-Ube Medical Center, Yamaguchi, Japan

    1 shared publication
  • Hiroshige Yoshioka

    Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan

    1 shared publication
  • I. Sekine

    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo

    1 shared publication

Latest Publications

  • Open Access

    A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503

    by Yoshihiko Segawa, Katsuyuki Kiura, Katsuyuki Hotta, Nagio Takigawa, Masahiro Tabata, Keitaro Matsuo, Hiroshige Yoshioka, Hidetoshi Hayashi, Haruyuki Kawai, Keisuke Aoe, et al.


    • 1 February 2010
      • Vol. 30  (2) , 557-63

    Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.

    by Toshiaki Takahashi, Nobuyuki Yamamoto, Toshihiro Nukiwa, Kiyoshi Mori, Masahiro Tsuboi, Takeshi Horai, Noriyuki Masuda, Kenji Eguchi, Tetsuya Mitsudomi, Soichiro Yokota, et al.

    The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC). This was a multicentre, open-label phase II study of erlotinib (150 mg/day) in patients with stage IIIB or IV NSCLC. The primary endpoint was the objective tumour response rate. Of the 46 patients, 13 were assessed to have a partial response and 9 had stable disease. The median duration of response was 449 days and time to progression was 75 days. Median overall survival (OS) was 13.5 months and the 1-year survival rate was 56.5%. The most common adverse events were dermal or gastrointestinal, and were mainly grade 2 or less. An exploratory analysis suggested a link between rash severity and OS. Erlotinib has promising antitumour activity and is generally well tolerated in Japanese patients with previously treated NSCLC.


  • A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

    by Y. Segawa, K. Aogi, K. Inoue, M. Sano, I. Sekine, Y. Tokuda, H. Isobe, T. Ogura, M. Tsuboi, S. Atagi

    The 5-HT(3) receptor antagonists (RAs) help maintain the standard of care, in various combinations with other agents, for prevention of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a new generation 5-HT(3) RA with indication not only acute but also delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC). This study was carried out to determine the optimal dosage of palonosetron in combination with dexamethasone in patients in Japan. This study evaluated the efficacy and safety of palonosetron in patients receiving MEC combined with dexamethasone. Patients received single doses of 0.075, 0.25, or 0.75 mg of palonosetron before MEC. Dexamethasone was infused before palonosetron, at 20 mg for the patients receiving paclitaxel (Taxol) and 8 mg for the patients not receiving paclitaxel. The primary end point was complete response (CR: no emetic episodes and no rescue medication) in the acute phase (0-24 h). In total, 204 patients (88 men, 116 women; 96 with paclitaxel, 108 without paclitaxel) were assessable for efficacy. No dose-response relationship was observed regarding the CR rate in the acute phase. CR rates increased dose dependently for delayed (24-120 h) and overall (0-120 h) phases in patients receiving anthracyclines and cyclophosphamide combination (AC/EC, n = 80); however, the difference in CR rates among doses was not statistically significant. The most commonly reported adverse events related to palonosetron were constipation and headache, confirming the class safety profile. This study indicates a statistically nonsignificant trend for the dose-response relationship for antiemetic protection in the delayed and overall phases in AC/EC patients (the regimen currently considered to be more emetogenic than MEC).